Tips and tricks from our application experts: AAV analysis with CE by Peter Holper | Jan 24, 2025 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemPeter Holper, Staff Applications Scientist at SCIEX, US, shares his tips and tricks on AAV analysis using CE with the BioPhase 8800 system and the PA 800 Plus system.
Plasmid manufacturing: Setting up your CGT programs for success by Kerstin Pohl | Nov 15, 2024 | Biopharma, BioPhase 8800 system, Blogs, PA 800 systemPlasmid DNA serves a variety of purposes, from critical starting material for proteins, mRNA, viral vectors, and drug substances. Below, Dr. Emma Bjorgum, the Vice President of Client Services of the DNA Business Unit at Aldevron and an expert in plasmid manufacturing, provided insights into the process and an outlook on the future.
Supporting new CRISPR gene editing systems by Kerstin Pohl | Apr 17, 2024 | Biopharma, Blogs, PA 800 systemPrime editing (PE) is a next-generation gene editing technology that utilizes a Cas9 protein fused to a prime editing guide ribonucleic acid (pegRNA) to achieve high CRISPR/Cas9 editing efficiency and precision. However, the length requirement of pegRNAs at 120–250 nucleotides (nt) and their high level of secondary structure formation present analytical challenges for the purity analysis of chemically synthesized pegRNAs during development and quality control (QC).
Beyond mRNA: how advances in analytical techniques are enabling a revolution in the RNA drug landscape by Kerstin Pohl | Nov 7, 2023 | Biopharma, Blogs, PA 800 systemCurrently, there are 3 main types of in vitro transcribed (IVT) RNA drugs. Two of these—conventional messenger RNA (mRNA) and base-modified mRNA (bmRNA), which incorporates chemically modified nucleotides—are non-replicating. The third type is self-replicating RNA (srRNA), which is based on an engineered viral genome but devoid of viral structural protein genes. Its self-replicating ability makes srRNA a promising tool for new therapeutic drugs.